STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review)
Biomedical Reports · 24.09.2024 · 21 (6)
DOI: 10.3892/br.2024.1863 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Reports, online erschienen am 24.09.2024. Verfasst von Liliana Cortés-Ballinas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 045…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Unidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México, Federico Gómez, Mexico City 06720, Mexico.
Zitieren
APA
Cortés-Ballinas, L., López-Pérez, T. V., & Rocha-Zavaleta, L. (2024). STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review). Biomedical Reports, 21(6). https://doi.org/10.3892/br.2024.1863
Vancouver
Cortés-Ballinas L, López-Pérez TV, Rocha-Zavaleta L. STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review). Biomedical Reports. 2024;21(6). doi:10.3892/br.2024.1863
BibTeX
@article{CortsBallinas2024,
author = {Cortés-Ballinas, Liliana and López-Pérez, Tania V and Rocha-Zavaleta, Leticia},
title = {STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review)},
journal = {Biomedical Reports},
year = {2024},
volume = {21},
number = {6},
doi = {10.3892/br.2024.1863}
}
EUVIMED